Study on the effect of functional movement on the recurrence of patients with ankylosing spondylitis after treat-to-target therapy
10.3760/cma.j.cn141217-20210722-00287
- VernacularTitle:达标后强直性脊柱炎患者功能动作筛查值对疾病复发的影响研究
- Author:
Min LI
1
;
Xiaohui WU
;
Min YANG
;
Yi LIANG
;
Jing XU
;
Cuiping WANG
;
Maoyi YANG
;
Jiepei SUN
;
Xu HE
;
Mingming HUANG
Author Information
1. 四川省骨科医院风湿骨关节病科，成都 610041
- Keywords:
Spondylitis, ankylosing;
Functional movement screen;
Treat-to-target;
Adalimumab;
Recurrence
- From:
Chinese Journal of Rheumatology
2022;26(1):9-13,C1
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of functional movement assessment on the recurrence of patients with ankylosing spondylitis (AS) after treat-to-target therapy.Methods:The clinical data of 61 patients with AS in Chengdu were collected including clinical symptoms and AS disease activity (ASDAS). After 24 weeks adalimumab treatment, motor function score of AS patients(ASDAS<1.3) was assessed by functional movement screen (FMS), then adalimumab was discontinued and the rest of the concurrent drugs were continued until the disease relapse or up to 1 year. The data of the two groups were compared using t-test analysis and Cox proportionate hazard model. Results:① The recurrence rate of patients with AS after treat-to-target therapy within 1 year follow-up was 57.4%; ② The recurrence group was younger [(27±7) vs (31±6), t=5.96, P=0.02], the ASADAS value was at the high end when adalimumab was withdrawal [(1.29±0.07) vs (0.87±0.16), t=177.31, P<0.01], and the FMS value was lower after treat-to-target [(12.9±2.7) vs (16.2±1.9), t=29.23, P<0.01], The time to reaching the treatment target was longer [(2.9±1.2) month vs (1.7±0.6) month, t=19.89, P<0.01] than the stable group; ③ The cut-off value of the FMS test of AS patients after treat-to-target therapy was 14.25 (sensitivity was 84.6%, specificity was 80%) . The time to treat-to-target was a risk factor for recurrence ( RR=2.285, P<0.05), and the FMS value after treat-to-target was a protective factor ( RR=0.625, P<0.05). Conclusion:After discontinuing the adalimumab, about half of the patients relapse. The time reaching the treatment target and the FMS value after treat-to-target therapy are the risk factors for disease recurrence.
